baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 06/24 BRM/ DE000HC8HEB6 /

2024-04-26 7:10:21 PM	Chg.-0.0010	Bid2024-04-26	Ask-	Underlying	Strike price	Expiration date	Option type
0.0020EUR	-33.33%	- Bid Size: 90,000	- Ask Size: -	Bristol Myers Squibb...	60.00 USD	2024-06-19	Call

GlobeNewswire 04-25 International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...

GlobeNewswire 04-25 Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract ...

GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 04-22 ArriVent Appoints Kristine Peterson to its Board of Directors

GlobeNewswire 04-08 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...

GlobeNewswire 04-08 Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

GlobeNewswire 04-08 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H.,...

GlobeNewswire 04-08 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

GlobeNewswire 04-05 Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies D...

GlobeNewswire 04-03 Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the...

GlobeNewswire 04-03 CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...

GlobeNewswire 04-02 MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered ...

GlobeNewswire 04-02 Indegene Hosts Inaugural Strategic Advisory Board Meeting Chaired By Renowned Global Biopharma Leade...

GlobeNewswire 04-02 Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

GlobeNewswire 04-01 Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Med...

GlobeNewswire 04-01 Autolus Therapeutics Announces Changes to its Board of Directors

GlobeNewswire 03-31 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...

GlobeNewswire 03-29 Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

GlobeNewswire 03-28 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...

GlobeNewswire 03-26 Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates...

GlobeNewswire 03-26 Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Cl...

GlobeNewswire 03-23 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Sq...

GlobeNewswire 03-21 CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

GlobeNewswire 03-21 Immatics Announces Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 03-21 Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nou...

UC WAR. CALL 06/24 BRM/ DE000HC8HEB6 /

If you wish to receive reply to your feedback, please provide your email address.